Stock Markets May 20, 2026 06:05 AM

Nestlé and Danone Stocks Edge Lower as Media Probe Raises Questions Over Recall Timing

Investigation scrutinizes pace of notifications after cereulide toxin found in supplier ingredient used in infant formula; Nestlé disputes some claims while prosecutors see no proven link to infant deaths

By Hana Yamamoto

Shares of Nestlé SA and Danone SA slipped but remained largely stable as a joint media investigation questioned how quickly the companies informed authorities and consumers after traces of the toxin cereulide were detected in an ingredient used in infant formula. Nestlé says it identified low levels in late November, halted use of the supplier’s ingredient on Dec. 24 and began public recalls on Jan. 5, while prosecutors have so far ruled out a connection between the recalled formula and infant fatalities.

Nestlé and Danone Stocks Edge Lower as Media Probe Raises Questions Over Recall Timing

Key Points

  • A joint investigation by Radio France, RTBF and RTS questioned the speed of recalls and notifications after cereulide was detected in an ingredient supplied by CABIO Biotech, affecting several infant formula makers including Nestlé, Danone and Lactalis.
  • Nestlé provided a timeline: low-level detection in late November, cessation of use of affected mixes on Dec. 24, supplier notified on Dec. 29, sample analysis through Jan. 3, and public recalls from Jan. 5; Nestlé disputes claims of "silent" withdrawals.
  • Prosecutors in Bordeaux and Angers have said they did not find a connection between infant deaths and the recalled formulas, and an inquiry in Meaux was reportedly transferred to Paris.

Overview

Shares in two of Europe's largest food groups, Nestlé SA and Danone SA, ticked down on Wednesday while markets absorbed renewed attention on their handling of a contaminated infant formula episode. The scrutiny follows a joint investigation by Radio France, RTBF and RTS that raised questions about the timing of product withdrawals and notifications to authorities.


What the investigation reported

The media outlets said tests uncovered cereulide, a toxin linked to vomiting and diarrhoea and considered particularly hazardous to infants, in an ingredient supplied by China’s CABIO Biotech. That ingredient, arachidonic acid oil, was reported to have been incorporated into infant formulas produced by a number of manufacturers, including Nestlé, Danone and Lactalis, prompting recalls across several countries.

According to the investigation, 838,000 cans of infant formula were held back from Dec. 26 at Nestlé’s facility in northern France and at other production sites. The report also said some products already in distribution channels or in consumers' homes remained without a public recall or immediate notification to European authorities. The outlets asserted that Nestlé performed so-called "silent" withdrawals in Austria and Germany from Dec. 24, and that Danone removed products from sale in January prior to issuing public recalls.


Companies' account of events

Nestlé provided a timeline stating it first detected low levels of cereulide in late November. The company said it ceased using mixes containing the supplier's arachidonic acid oil once contamination was confirmed on Dec. 24, notified the supplier on Dec. 29, analysed samples through Jan. 3 to gauge the problem's extent, and initiated public recall actions beginning Jan. 5. Nestlé disputed the characterisation that it carried out silent withdrawals.


Legal and investigatory status

Prosecutors in Bordeaux and Angers have indicated they did not find a link between the deaths of infants and the batches of baby formula that were recalled. Separately, Radio France reported that an inquiry opened in Meaux was transferred to Paris.


Market context

Equity moves were modest: the shares slipped but did not register large swings, reflecting investor attention to both the reputational and operational questions raised by the reporting, as well as to the companies' public statements and ongoing legal inquiries.


Summary

A joint media investigation has questioned whether Nestlé and Danone acted promptly in alerting authorities and consumers after cereulide was found in an ingredient supplied by CABIO Biotech. Nestlé has set out a timeline that includes initial detection in late November and public recalls from Jan. 5, and prosecutors have said they have not established a link between recalled formula and infant deaths.

Risks

  • Regulatory and reputational risk for infant formula manufacturers and the broader food sector due to questions about recall timing and communication to authorities and consumers.
  • Supply-chain contamination risk stemming from an ingredient supplied by CABIO Biotech, which affected multiple manufacturers and triggered cross-border product recalls impacting production and distribution channels.
  • Ongoing investigations and legal scrutiny, including inquiries transferred between jurisdictions, which create uncertainty for affected companies and could influence operations and market perceptions.

More from Stock Markets

S&P Global Upholds Fast-Entry Rules Ahead of SpaceX Public Debut Jun 4, 2026 Insperity Shares Climb After CEO Buys 233,000 Shares Jun 4, 2026 SpaceX Signals Firmness on $135 IPO Price as Roadshow Begins Jun 4, 2026 CME Chief Warns CFTC Approval of Perpetual Crypto Futures Could Create Systemic Risk Jun 4, 2026 AmperCap Raises $125 Million in NASDAQ Listing as It Targets U.S.-Mexico Middle-Market Deals Jun 4, 2026